# Mentari Therapeutics, Inc. (MTRI)

> Source: Nexqual · https://nexqual.com/MTRI · data as of 2026-11-18 21:00 UTC · cite as "Nexqual, Mentari Therapeutics, Inc. (MTRI), nexqual.com/MTRI" · informational, not investment advice.

## MTRI major shareholder filing: Schedule 13D, Nov 12, 2026
Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Peter Evan Harwin filed a Schedule 13D on Nov 12, 2026, reporting up to 19.99% of the class (more than 5% owner that may seek to influence the company). Item 4, Purpose of Transaction, quoted:

> The Reporting Persons own 19.99% of the Company in the aggregate, based upon the Company's aggregate outstanding shares as of November 6, 2026. The Reporting Persons' securities include 10,555,507 shares of Common Stock directly held by Fund II, and exclude (i) 4,013,000 shares of Common Stock issuable upon conversion of 4,013 shares of Series A Preferred Stock directly held by Fund II and (ii) 1,468,222 shares of Common Stock issuable upon exercise of Pre-Funded Warrants directly held by Fund II. The exercise of the Pre-Funded Warrants is subject to a beneficial ownership limitation of 19.99% of the outstanding shares of Common Stock and the conversion of the Series A Preferred Stock is subject to a beneficial ownership limitation of 19.99% of the outstanding shares of Common Stock. The securities exclude shares of Common Stock issuable upon exercise of Pre-Funded Warrants and conversion of Series A Preferred Stock in excess of such beneficial ownership limitations. At such time as Fairmount and its affiliates beneficially own 9.0% or less of the outstanding shares of Common Stock, the beneficial ownership limitation with respect to the Series A Preferred Stock will automatically reduce to 9.99%. …

Source: https://www.sec.gov/Archives/edgar/data/1728328/000119312526458677/0001193125-26-458677-index.htm

**Price:** USD 15.29 (-12.66% on the day) · last close of Nov 18, 2026; US market after hours, not a live price. Prev close 17.5 · day 14.78–18.12 · 52w 5.75–23.3 · market cap $891M · NCM

## Key facts
- Insider open-market purchases, last ~7 months: 12 Form 4 filings, $1.4M; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: Buy (mean 2.00 on a 1–5 scale) (2 analysts), mean target USD 33 (range 33–33).
- Total return with dividends: 1Y +3.5% vs S&P 500 +11.4%; 5Y -99.8% vs S&P 500 +66.5%.
- Next earnings: 2027-02-10 (date not yet confirmed by the company), EPS estimate USD —, revenue estimate $0K.
- Dividend: MTRI paid no cash dividend in the last five years.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $1.4M | $4.1M | $4.6M | $4.9M | — | — |
| Gross profit | $544K | $1.4M | $1.1M | $1.7M | — | — |
| Operating income | -$18.6M | -$7.9M | — | — | — | — |
| Net income | -$18.6M | -$7.9M | -$7.7M | -$8.2M | -$12.6M | -$13.2M |
| EPS (diluted) | -$6634.00 | -$650.00 | -$201.40 | -$83.60 | -$31.20 | — |
| Free cash flow | -$15.6M | -$7.4M | -$7.0M | — | — | — |
| Gross margin | 39.8% | 33.9% | 23.9% | 34.5% | — | — |
| Operating margin | -1361.9% | -192.2% | — | — | — | — |
| Net margin | -1361.9% | -192.2% | -166.9% | -165.1% | — | — |
| Revenue growth | -28.3% | +202.8% | +11.2% | +7.5% | — | — |
| Cash + short-term investments | $6.2M | $9.0M | $6.6M | $11.1M | $2.2M | — |
Fiscal years end Jun. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Sep 30, 2026)
Earnings yield -1.49%

## Insider purchases (SEC Form 4, open-market, last ~7 months)
12 purchases, $1.4M. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-11-05 | Adar1 Capital Management, Llc |  | 2,640 | $35K | 13.1 | Too little history (no open-market trades in 2023–2025) |
| 2026-10-23 | Adar1 Capital Management, Llc |  | 4 | $0K | 1.32 | Too little history (no open-market trades in 2023–2025) |
| 2026-10-16…2026-10-19 | Adar1 Capital Management, Llc |  | 1,087 | $1K | 1.32 | Too little history (no open-market trades in 2023–2025) |
| 2026-10-13…2026-10-15 | Adar1 Capital Management, Llc |  | 9,569 | $13K | 1.33 | Too little history (no open-market trades in 2023–2025) |
| 2026-10-06…2026-10-08 | Adar1 Capital Management, Llc |  | 10,903 | $14K | 1.33 | Too little history (no open-market trades in 2023–2025) |
| 2026-10-01…2026-10-05 | Adar1 Capital Management, Llc |  | 42,920 | $57K | 1.33 | Too little history (no open-market trades in 2023–2025) |
| 2026-09-14…2026-09-16 | Adar1 Capital Management, Llc |  | 91,101 | $118K | 1.3 | Too little history (no open-market trades in 2023–2025) |
| 2026-07-14…2026-07-16 | Vivo Opportunity, Llc |  | 20,546 | $32K | 1.55 | Too little history (no open-market trades in 2023–2025) |
| 2026-07-15 | Adar1 Capital Management, Llc |  | 1,000 | $2K | 1.55 | Too little history (no open-market trades in 2023–2025) |
| 2026-06-30…2026-07-02 | Vivo Opportunity, Llc |  | 6,551 | $10K | 1.55 | Too little history (no open-market trades in 2023–2025) |
| 2026-05-20…2026-06-08 | Vivo Opportunity, Llc |  | 249,227 | $392K | 1.57 | Too little history (no open-market trades in 2023–2025) |
| 2026-05-19 | Adar1 Capital Management, Llc |  | 468,551 | $722K | 1.54 | Too little history (no open-market trades in 2023–2025) |
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Consensus Buy (mean 2.00 on a 1–5 scale), 2 analysts; mean target USD 33 (low 33, high 33).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-11-10 | Jefferies | Initiated | Buy | $30 |
| 2026-11-10 | Stifel | Initiated | Buy | $30 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-11-18) | 5Y (from 2021-11-15) |
|---|---|---|
| Total return | +3.5% | -99.8% |
| S&P 500 (SPY) | +11.4% | +66.5% |
| Per year | +3.5% | -72.1% |
| Volatility (annualized) | 124.3% | 117.1% |
| Max drawdown | -57.9% (Nov 2025→Mar 2026) | -99.9% (Nov 2021→May 2026) |

## Dividends
MTRI paid no cash dividend in the last five years.

## Peers (Biotechnology)
BLTE (Belite Bio, Inc) USD 156.23 -0.94% · KOD (Kodiak Sciences Inc) USD 97.81 +1.04% · ORKA (Oruka Therapeutics, Inc.) USD 95.74 -0.60% · IMVT (Immunovant, Inc.) USD 33.17 -0.12% · AXSM (Axsome Therapeutics, Inc.) USD 134 -1.43% · IBRX (ImmunityBio, Inc.) USD 6.7 +7.03%

## More
Full page: https://nexqual.com/MTRI · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in MTRI's own 10-K filed 2026-09-09 (https://www.sec.gov/Archives/edgar/data/1728328/000121390026098419/ea0301263-10k_inmed.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Customer | BayMedica | "Since our inception, we have generated revenue from BayMedica product sales and no sales from any other sources and have incurred significant operating losses and negative cash flows from our operations." |

## Customer concentration

In the quarter ended Dec 31, 2025, 4 direct customers each accounted for at least 10% of MTRI's revenue (30%, 19%, 12%, 10%; 71% combined). The company does not name these customers in the filing. (10-Q, filed 2026-02-11)

## Company outlook (8-K filed 2026-11-16)

- "The results for the three and nine months ended September 30, 2026 are not necessarily indicative of results that may be expected for the year ending December 31, 2026 or any other interim period or for any future year."
- "F-11 vesting conditions, the expected term of the Company's stock options has been determined utilizing the "simplified" method for awards that qualify as "plain-vanilla" stock options."
- "The grant dates for the issuance of warrants were expected to be December 31, 2025 and December 31, 2026 (if the term with respect to all Research Programs is still active), respectively, as all terms of the award, including number of shares and exercise price, will be known by all parties by this date."
- "As of September 30, 2026, total unrecognized compensation cost related to the unvested RSAs was $0.1 million, which is expected to be recognized over a weighted average period of 2.9 years."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter | — | — | — | $0 | — |
| Current fiscal year (ends 2027-06-30) | $-1.75 | $0.00 | −$1.75 | $0 | 1 |
| Next fiscal year | — | — | — | $0 | — |

## Recent SEC filings (last 120 days)
| Filed | Form | What it says | Filing |
|---|---|---|---|
| 2026-11-16 | Schedule 13G/A | Squadron Master Fund LP, Squadron Capital Management LLC: 0.0% of shares, passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1728328/000205070926000034/0002050709-26-000034-index.htm |
| 2026-11-16 | 8-K | Completed an acquisition or sale of assets; Quarterly results — “Financial Information Unaudited Financial Statements The unaudited condensed consolidated financial statements of Mentari as of September 30, 2026 and for the three and nine months ended September 30, 2026 and related notes thereto are attached hereto as Exhibit 99.1 and incorporated herein by reference. Management's Discussion and Analysis of Financial Condition and Results of Operations Mentari's Management's Discussion and Analysis of Financial Condition and Results of Operations for the three and nine months…” | https://www.sec.gov/Archives/edgar/data/1728328/000119312526462017/0001193125-26-462017-index.htm |
| 2026-11-13 | Schedule 13G | Commodore Capital LP, Commodore Capital Master LP: 5.6% of shares, passive 5%+ holder | https://www.sec.gov/Archives/edgar/data/1728328/000183194226000046/0001831942-26-000046-index.htm |
| 2026-11-13 | Schedule 13G | Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd.: 5.6% of shares, passive 5%+ holder | https://www.sec.gov/Archives/edgar/data/1728328/000117266126005030/0001172661-26-005030-index.htm |
| 2026-11-12 | Schedule 13D | Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P.: 20.0% of shares, 5%+ holder that may seek to influence the company — “The Reporting Persons own 19.99% of the Company in the aggregate, based upon the Company's aggregate outstanding shares as of November 6, 2026. The Reporting Persons' securities include 10,555,507 shares of Common Stock directly held by Fund II, and exclude (i) 4,013,000 shares…” | https://www.sec.gov/Archives/edgar/data/1728328/000119312526458677/0001193125-26-458677-index.htm |
| 2026-11-10 | 8-K | Entered a material agreement; Completed an acquisition or sale of assets; Quarterly results; Unregistered sale of shares; Change to shareholder rights; Change in control; Director or executive officer change, or pay arrangement; Bylaws or fiscal-year change; Code of ethics change or waiver; Item 5.06 — “The information set forth under the headings " Contingent Value Rights Agreement " and " Registration Rights Agreement " in the Introductory Note of this Current Report on Form 8-K is incorporated by reference into this Item 1.01. Indemnification Agreements On November 6, 2026, the Company entered into indemnification agreements with each of its directors and executive officers (collectively, the " Indemnitees ," and such agreements, the " Indemnification Agreements "), which replaced and superseded any previous…” | https://www.sec.gov/Archives/edgar/data/1728328/000119312526455640/0001193125-26-455640-index.htm |
| 2026-11-09 | 8-K | Regulation FD disclosure | https://www.sec.gov/Archives/edgar/data/1728328/000119312526452706/0001193125-26-452706-index.htm |
| 2026-11-05 | 8-K | Regulation FD disclosure | https://www.sec.gov/Archives/edgar/data/1728328/000106299326005760/0001062993-26-005760-index.htm |
| 2026-11-05 | 8-K | Bylaws or fiscal-year change; Shareholder vote results; Other material event — “On November 4, 2026, the Company held its Shareholders Meeting, at which the proposals set forth below, relating to the Merger Agreement and other matters, were submitted to the Company's shareholders. The proposals are described in detail in the Company's proxy statement/prospectus, dated October 1, 2026 and included as part of the Company's registration statement on Form S-4 (File No. 333-297234) (the "Proxy Statement"). There were 5,493,735 Common Shares outstanding and entitled to vote on September 25, 2026,…” | https://www.sec.gov/Archives/edgar/data/1728328/000119312526448367/0001193125-26-448367-index.htm |
| 2026-11-03 | 8-K | Regulation FD disclosure | https://www.sec.gov/Archives/edgar/data/1728328/000106299326005723/0001062993-26-005723-index.htm |
| 2026-11-03 | 10-Q | Quarterly report · period ended Sep 30, 2026 | https://www.sec.gov/Archives/edgar/data/1728328/000121390026115083/0001213900-26-115083-index.htm |
| 2026-11-02 | 425 | Merger or acquisition communication | https://www.sec.gov/Archives/edgar/data/1728328/000119312526443834/0001193125-26-443834-index.htm |
| 2026-10-27 | 425 | Merger or acquisition communication | https://www.sec.gov/Archives/edgar/data/1728328/000119312526432362/0001193125-26-432362-index.htm |
| 2026-10-07 | Schedule 13G/A | ADAR1 Capital Management, LLC, Daniel Schneeberger: 17.2% of shares, passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1728328/000110465926114415/0001104659-26-114415-index.htm |
Source: SEC EDGAR. Quotes are the opening words of each item as filed.
